Frontiers in neurology · 2026
Ultrasound-guided continuous radiofrequency of the C2 dorsal root ganglion for menstrually related migraine: a comparative clinical study.
СтатьяСравнительное исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Heng, Yang Liqiang, Liang Jing, Zhou Weigang, He Liangliang
Аннотация
BACKGROUND: Menstrually related migraine (MRM) is a common migraine subtype in women and is often accompanied by gastrointestinal symptoms, anxiety, and depression, leading to substantial functional impairment. Conventional pharmacological treatments show limited efficacy in improving long-term symptoms and quality of life. This study aimed to compare the clinical effectiveness of ultrasound-guided continuous radiofrequency (CRF) of the C2 dorsal root ganglion with conventional zolmitriptan therapy in patients with MRM.
METHODS: This retrospective comparative observational study (using prospectively collected clinical data) included 69 patients with MRM treated between January and December 2024. Patients were assigned to a conventional medication group receiving oral zolmitriptan (Group C, n = 34) or an ultrasound-guided C2 dorsal root ganglion CRF group (Group R, n = 35) based on clinical decision-making. Headache intensity (NRS), attack frequency and duration, nausea and vomiting (VRS), anxiety (HAMA), depression (HAMD), and migraine-related disability (MIDAS) were assessed at baseline and up to 6 months post-treatment. Treatment efficacy and adverse events were assessed at baseline and up to 6 months post-treatment.
RESULTS: Both groups showed significant improvements in headache symptoms and functional outcomes compared with baseline (p < 0.001). In the CRF group, significant improvements were observed across all outcome measures from baseline to 6 months, including NRS pain scores (7.5 ± 0.9 to 3.6 ± 0.7), attack frequency and duration, anxiety, depression, and disability scores (all p < 0.001). Between-group comparison showed greater improvements in Group R compared with Group C across multiple time points; however, this comparison should be interpreted with caution given the non-guideline-concordant zolmitriptan regimen.
CONCLUSION: In this retrospective comparative observational study, ultrasound-guided continuous radiofrequency of the C2 dorsal root ganglion was associated with greater improvements in headache symptoms, psychological status, and functional disability compared with oral zolmitriptan therapy in patients with MRM, with a favorable safety profile. These findings should be interpreted with caution given the different treatment modalities and study design limitations.
TRIAL REGISTRATION: This study was registered in the Chinese Clinical Trial Registry (ChiCTR2500095771).
METHODS: This retrospective comparative observational study (using prospectively collected clinical data) included 69 patients with MRM treated between January and December 2024. Patients were assigned to a conventional medication group receiving oral zolmitriptan (Group C, n = 34) or an ultrasound-guided C2 dorsal root ganglion CRF group (Group R, n = 35) based on clinical decision-making. Headache intensity (NRS), attack frequency and duration, nausea and vomiting (VRS), anxiety (HAMA), depression (HAMD), and migraine-related disability (MIDAS) were assessed at baseline and up to 6 months post-treatment. Treatment efficacy and adverse events were assessed at baseline and up to 6 months post-treatment.
RESULTS: Both groups showed significant improvements in headache symptoms and functional outcomes compared with baseline (p < 0.001). In the CRF group, significant improvements were observed across all outcome measures from baseline to 6 months, including NRS pain scores (7.5 ± 0.9 to 3.6 ± 0.7), attack frequency and duration, anxiety, depression, and disability scores (all p < 0.001). Between-group comparison showed greater improvements in Group R compared with Group C across multiple time points; however, this comparison should be interpreted with caution given the non-guideline-concordant zolmitriptan regimen.
CONCLUSION: In this retrospective comparative observational study, ultrasound-guided continuous radiofrequency of the C2 dorsal root ganglion was associated with greater improvements in headache symptoms, psychological status, and functional disability compared with oral zolmitriptan therapy in patients with MRM, with a favorable safety profile. These findings should be interpreted with caution given the different treatment modalities and study design limitations.
TRIAL REGISTRATION: This study was registered in the Chinese Clinical Trial Registry (ChiCTR2500095771).